Skip to main content
Top
Published in: Medical Oncology 4/2015

01-04-2015 | Original Paper

Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents

Authors: Göknur Kara, Sema Tuncer, Mustafa Türk, Emir Baki Denkbaş

Published in: Medical Oncology | Issue 4/2015

Login to get access

Abstract

ATP-binding cassette E1 (ABCE1) is involved in several biological functions in cancer cells such as tumor proliferation, antiapoptotic pathway and chemoresistance mechanism. This work aimed to investigate the alterations in chemosensitivity of A549 lung cancer cells for 5-Fluorouracil (5-FU) and irinotecan by silencing ABCE1 using specific small interfering RNAs (siRNA). The cells were treated with low doses of drugs, alone and also their combinations with ABCE1 siRNA. Cytotoxicity, cell proliferation and apoptosis/necrosis evaluations were performed in order to examine the effects of the combined treatment. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to confirm the downregulation of ABCE1. We also investigated the levels of B cell lymphoma 2 (Bcl-2) and mammalian target of rapamycin (mTOR) after the treatments by RT-PCR. Downregulation of ABCE1 improved the anticancer effects of 5-FU in inducing cell viability/proliferation inhibition and apoptosis/necrosis, whereas interestingly, almost did not change or slightly reduced the anticancer effects of irinotecan. ABCE1 expression significantly decreased by transfecting the cells with ABCE1 siRNA. Moreover, Bcl-2 and mTOR levels changed after the single or combined therapy in parallel with the apoptotic and antiproliferation effect. In conclusion, the simultaneous treatment of lung cancer cells with ABCE1 siRNA and 5-FU exhibited synergistic or additive effects; however, ABCE1 siRNA and irinotecan had unexpected antagonistic effects. Our findings demonstrate that the strategy of downregulation of ABCE1 may be included in conventional 5-FU chemotherapy for lung cancer, minimizing the usage of 5-FU at high dosages.
Literature
1.
go back to reference Yilmaz HH, Yazihan N, Tunca D, Sevinc A, Olcayto EO, Ozgul N, et al. Cancer trends and incidence and mortality patterns in Turkey. Jpn J Clin Oncol. 2011;41:10–6.CrossRefPubMed Yilmaz HH, Yazihan N, Tunca D, Sevinc A, Olcayto EO, Ozgul N, et al. Cancer trends and incidence and mortality patterns in Turkey. Jpn J Clin Oncol. 2011;41:10–6.CrossRefPubMed
2.
go back to reference Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids. 2013;2:1–11.CrossRef Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids. 2013;2:1–11.CrossRef
4.
go back to reference Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014;474:112–22.CrossRefPubMed Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014;474:112–22.CrossRefPubMed
5.
go back to reference Chen XQ, Yang S, Li ZY, Lu HS, Kang MQ, Lin TY. Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol Med Rep. 2012;5:917–22.PubMedCentralPubMed Chen XQ, Yang S, Li ZY, Lu HS, Kang MQ, Lin TY. Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol Med Rep. 2012;5:917–22.PubMedCentralPubMed
6.
go back to reference Barnes MN, Deshane JS, Rosenfeld M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: a review. Obstet Gynecol. 1997;89:145–55.CrossRefPubMed Barnes MN, Deshane JS, Rosenfeld M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: a review. Obstet Gynecol. 1997;89:145–55.CrossRefPubMed
7.
9.
go back to reference Caplen NJ. Gene therapy progress and prospects. Down regulating gene expression: the impact of RNA interference. Gene Ther. 2004;11:1241–8.CrossRefPubMed Caplen NJ. Gene therapy progress and prospects. Down regulating gene expression: the impact of RNA interference. Gene Ther. 2004;11:1241–8.CrossRefPubMed
10.
11.
go back to reference Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm. 2012;80:268–73.CrossRefPubMed Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm. 2012;80:268–73.CrossRefPubMed
12.
go back to reference Sun TM, Du JZ, Yao YD, Mao CQ, Dou S, Huang SY, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5:1483–94.CrossRefPubMed Sun TM, Du JZ, Yao YD, Mao CQ, Dou S, Huang SY, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5:1483–94.CrossRefPubMed
13.
go back to reference Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61:1203–13.CrossRefPubMed Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61:1203–13.CrossRefPubMed
14.
go back to reference Kim E, Jung Y, Choi Y, Yang J, Suh JS, Huh YM, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 2010;31:4592–9.CrossRefPubMed Kim E, Jung Y, Choi Y, Yang J, Suh JS, Huh YM, et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 2010;31:4592–9.CrossRefPubMed
15.
go back to reference Tian Y, Han X, Tian DL. The biological regulation of ABCE1. Life. 2012;64:795–800.PubMed Tian Y, Han X, Tian DL. The biological regulation of ABCE1. Life. 2012;64:795–800.PubMed
16.
go back to reference Le Roy F, Bisbal C, Silhol M, Martinand C, Lebleu B, Salehzada T. The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells. J Biol Chem. 2001;276:48473–82.CrossRefPubMed Le Roy F, Bisbal C, Silhol M, Martinand C, Lebleu B, Salehzada T. The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells. J Biol Chem. 2001;276:48473–82.CrossRefPubMed
17.
go back to reference Huang B, Gao Y, Tian D, Zheng M. A small interfering ABCE1-targeting RNA inhibits the proliferation and invasiveness of small cell lung cancer. Int J Mol Med. 2010;25:687–93.PubMed Huang B, Gao Y, Tian D, Zheng M. A small interfering ABCE1-targeting RNA inhibits the proliferation and invasiveness of small cell lung cancer. Int J Mol Med. 2010;25:687–93.PubMed
18.
go back to reference Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, et al. Alteration in copy numbers genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403–10.CrossRefPubMed Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, et al. Alteration in copy numbers genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403–10.CrossRefPubMed
19.
go back to reference Roche Diagnostics GmbH. Introduction of the RTCA SP instrument. RTCA SP instrument operator‘s manual, A. Acea Biosciences, Inc: 2008. pp. 14–16. Roche Diagnostics GmbH. Introduction of the RTCA SP instrument. RTCA SP instrument operator‘s manual, A. Acea Biosciences, Inc: 2008. pp. 14–16.
20.
go back to reference Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX. Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent Mater. 2010;26:51–8.CrossRefPubMed Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX. Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent Mater. 2010;26:51–8.CrossRefPubMed
21.
go back to reference Ramis G, Martinez-Alarcon L, Quereda JJ, Mendonca L, Majado MJ, Gomez-Coelho K, et al. Optimization of cytotoxicity assay by real-time, impedance-based cell analysis. Biomed Microdevices. 2013;15:985–95.CrossRefPubMed Ramis G, Martinez-Alarcon L, Quereda JJ, Mendonca L, Majado MJ, Gomez-Coelho K, et al. Optimization of cytotoxicity assay by real-time, impedance-based cell analysis. Biomed Microdevices. 2013;15:985–95.CrossRefPubMed
22.
go back to reference Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551–69.CrossRefPubMed Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551–69.CrossRefPubMed
23.
go back to reference Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299–313.CrossRefPubMed Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299–313.CrossRefPubMed
24.
go back to reference Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998;25:887–95.CrossRefPubMed Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998;25:887–95.CrossRefPubMed
25.
go back to reference Ikeda R, Vermeulen LC, Lau E, Jiang Z, Pomplun M, Kolesar JM. Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. Mol Med Rep. 2010;3:1031–4.PubMed Ikeda R, Vermeulen LC, Lau E, Jiang Z, Pomplun M, Kolesar JM. Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. Mol Med Rep. 2010;3:1031–4.PubMed
26.
go back to reference Hardman WE, Moyer MP, Cameron IL. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer. 1999;81:440–8.CrossRefPubMedCentralPubMed Hardman WE, Moyer MP, Cameron IL. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer. 1999;81:440–8.CrossRefPubMedCentralPubMed
27.
go back to reference Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. Mol Aspects Med. 2007;28:143–66.CrossRefPubMed Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. Mol Aspects Med. 2007;28:143–66.CrossRefPubMed
28.
go back to reference Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci. 2010;101:1163–9.CrossRefPubMed Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci. 2010;101:1163–9.CrossRefPubMed
29.
go back to reference Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene. 2007;26:5793–807.CrossRefPubMed Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene. 2007;26:5793–807.CrossRefPubMed
30.
go back to reference Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, et al. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 2009;100:903–13.CrossRefPubMed Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, et al. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 2009;100:903–13.CrossRefPubMed
31.
go back to reference Pisarev A, Skabkin MA, Pisareva VP, Skabkina OV, Rakotondrafara AM, Hentze MW, et al. The role of ABCE1 in eukaryotic post-termination ribosomal recycling. Mol Cell. 2010;37:196–210.CrossRefPubMedCentralPubMed Pisarev A, Skabkin MA, Pisareva VP, Skabkina OV, Rakotondrafara AM, Hentze MW, et al. The role of ABCE1 in eukaryotic post-termination ribosomal recycling. Mol Cell. 2010;37:196–210.CrossRefPubMedCentralPubMed
32.
go back to reference Chen ZQ, Dong J, Ishimura A, Daar I, Hinnebusch AG, Dean M. The essential vertebrate ABCE1 protein interacts with eukaryotic initiation factors. J Biol Chem. 2006;281:7452–7.CrossRefPubMed Chen ZQ, Dong J, Ishimura A, Daar I, Hinnebusch AG, Dean M. The essential vertebrate ABCE1 protein interacts with eukaryotic initiation factors. J Biol Chem. 2006;281:7452–7.CrossRefPubMed
33.
go back to reference Zheng MG, Gao Y, Huang B, Tian DL, Yang CL. Suppression of ABCE1 leads to decreased cell proliferation and increased apoptosis in 95-D/NCI-H446 lung carcinoma cells. Prog Biochem Biophys. 2009;36:1475–82.CrossRef Zheng MG, Gao Y, Huang B, Tian DL, Yang CL. Suppression of ABCE1 leads to decreased cell proliferation and increased apoptosis in 95-D/NCI-H446 lung carcinoma cells. Prog Biochem Biophys. 2009;36:1475–82.CrossRef
34.
go back to reference Koivusalo R, Krausz E, Helenius H, Hietanen S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol. 2005;68:372–82.PubMed Koivusalo R, Krausz E, Helenius H, Hietanen S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol. 2005;68:372–82.PubMed
35.
go back to reference Koga K, Hattori Y, Komori M, Narishima R, Yamasaki M, Hakoshima M, et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 2010;101:941–7.CrossRefPubMed Koga K, Hattori Y, Komori M, Narishima R, Yamasaki M, Hakoshima M, et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 2010;101:941–7.CrossRefPubMed
36.
go back to reference Zhang Y, Peng L, Mumper RJ, Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials. 2013;34:8459–68.CrossRefPubMedCentralPubMed Zhang Y, Peng L, Mumper RJ, Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials. 2013;34:8459–68.CrossRefPubMedCentralPubMed
37.
go back to reference Liu X, Yao X, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998;58:4245–9.PubMed Liu X, Yao X, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998;58:4245–9.PubMed
38.
go back to reference Bohm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest. 2009;39:395–405.CrossRefPubMed Bohm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest. 2009;39:395–405.CrossRefPubMed
Metadata
Title
Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents
Authors
Göknur Kara
Sema Tuncer
Mustafa Türk
Emir Baki Denkbaş
Publication date
01-04-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0557-3

Other articles of this Issue 4/2015

Medical Oncology 4/2015 Go to the issue